Year All20242023202220212020201920182017201620152014 Abivax reports 2022 financial results and operations update April 19, 2023 Read More Abivax appoints Michael Ferguson as Chief Commercial Officer April 18, 2023 Read More Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis April 17, 2023 Read More Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair April 05, 2023 Read More Abivax adjusts its 2023 Financial Communication Calendar March 16, 2023 Read More Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution March 13, 2023 Read More Abivax publishes a prospectus in the context of its capital increase February 23, 2023 Read More Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors February 22, 2023 Read More Abivax Appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer February 17, 2023 Read More Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO February 14, 2023 Read More
Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis April 17, 2023 Read More
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair April 05, 2023 Read More
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution March 13, 2023 Read More
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors February 22, 2023 Read More
Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO February 14, 2023 Read More
